Patients who continue to have symptoms despite PPI therapy are considered to have refractory GERD, usually defined as the persistence of typical symptoms unresponsive to steady doses of PPIs twice daily. days for at least 12 weeks of treatment. Up to 30% of GERD patients have treatment-resistant GERD.

Patients who continue to have symptoms despite PPI therapy are considered to have refractory GERD, usually defined as the persistence of typical symptoms unresponsive to steady doses of PPIs twice daily. days for at least 12 weeks of treatment. Up to 30% of GERD patients have treatment-resistant GERD.

Patients who continue to have symptoms despite PPI therapy are considered to have refractory GERD, usually defined as the persistence of typical symptoms unresponsive to steady doses of PPIs twice daily. days for at least 12 weeks of treatment. Up to 30% of GERD patients have treatment-resistant GERD.

Eosinophilic esophagitis (eosinophilic esophagitis) is a chronic, immune-mediated disease caused by food allergens, presenting with symptoms of dysfunction. esophagitis and esophagitis dominated by eosinophils.

Eosinophilic esophagitis (EoE) is a chronic, immunological or antigenic esophageal disorder that is clinically characterized by symptoms of esophageal dysfunction and histologically by invasion infiltration of eosinophils in the esophageal epithelium.

Eosinophilic esophagitis (eosinophilic esophagitis) is a chronic, immune-mediated disease caused by food allergens, presenting with symptoms of dysfunction. esophagitis and esophagitis dominated by eosinophils. Recent consensus guidelines now include proton pump inhibitor therapy as an alternative first-line treatment. This review will discuss why proton pump inhibitors are currently being used as a first-line treatment strategy.

Eosinophilic esophagitis (eosinophilic esophagitis) is a chronic, immune-mediated disease caused by food allergens, presenting with symptoms of dysfunction. esophagitis and esophagitis dominated by eosinophils.

Helicobacter pylori is the main cause of stomach ulcers and many other diseases. Currently, there are many methods to treat H. Accordingly, antacids prescribed to treat this disease have also yielded many good results.

Acid-suppressing drugs are the first-line therapy for esophageal disorders such as reflux esophagitis, erosive esophagitis, and Barrett's esophagus. The primary mechanical action of PPIs is to reduce gastric acid production by inhibiting the hydrogen-potassium ATPase pump, a transmembrane protein responsible for the release of hydrochloric acid into the gastric lumen.